Home > Journals > Giornale Italiano di Dermatologia e Venereologia > Past Issues > Giornale Italiano di Dermatologia e Venereologia 2017 August;152(4) > Giornale Italiano di Dermatologia e Venereologia 2017 August;152(4):355-9

CURRENT ISSUE
 

ARTICLE TOOLS

Publication history
Reprints
Cite this article as

GIORNALE ITALIANO DI DERMATOLOGIA E VENEREOLOGIA

A Journal on Dermatology and Sexually Transmitted Diseases


Official Journal of the Italian Society of Dermatology and Sexually Transmitted Diseases
Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,311


eTOC

 

REVIEW  


Giornale Italiano di Dermatologia e Venereologia 2017 August;152(4):355-9

DOI: 10.23736/S0392-0488.16.05358-X

Copyright © 2016 EDIZIONI MINERVA MEDICA

language: English

Sentinel lymph node biopsy in cutaneous melanoma

Simone RIBERO 1, 2, 3 , Eugenio SPORTOLETTI BADUEL 1, Simona OSELLA-ABATE 4, Emi DIKA 5, Pietro QUAGLINO 2, Franco PICCIOTTO 1, Giuseppe MACRIPÒ 1, Veronique BATAILLE 3

1 Section of Dermatologic Surgery, Department of Oncology, Città della Salute e della Scienza di Torino Hospital, Turin, Italy; 2 Section of Dermatology, Department of Medical Sciences, University of Turin, Turin Italy; 3 Department of Twins Research and Genetic Epidemiology, King’s College London, London, UK; 4 Section of Surgical Pathology, Department of Medical Sciences, University of Turin, Turin, Italy; 5 Dermatology Department, University of Bologna, Bologna, Italy


PDF  


The management of melanoma is constantly evolving. New therapies and surgical advances have changed the landscape over the last years. Since being introduced by Dr Donald Morton, the role of sentinel lymph node has been debated. In many melanoma centers, sentinel node biopsy is not a standard of care for melanoma above 1 mm in thickness. The results of the MSLT-II Trial are not available for a while and in the meantime, this procedure is offered as a prognostic indicator as it has been shown to be very useful for assessing risk of relapse. The biology of lymph node spread in melanoma is a complex field and there are many factors which influence it such as age, melanoma body site, thickness but other factors such as regression, ulceration and gender need further evaluation. In this review, we address the clinical value of sentinel lymph node biopsy and how its indication has changed over the years especially recently with the setup of many adjuvant trials which are offered to stage 3 melanomas.


KEY WORDS: Sentinel lymph node - Melanoma - Neoplasms - Prognosis

top of page

Publication History

Issue published online: June 14, 2017
Article first published online: June 1, 2016
Manuscript accepted: May 30, 2016
Manuscript revised: May 10, 2016
Manuscript received: March 8, 2016

Cite this article as

Ribero S, Sportoletti Baduel E, Osella-Abate S, Dika E, Quaglino P, Picciotto F, et al. Sentinel lymph node biopsy in cutaneous melanoma. G Ital Dermatol Venereol 2017;152:355-9. DOI: 10.23736/S0392-0488.16.05358-X

Corresponding author e-mail

Simone.ribero@unito.it